FDA
-
-
-
-
-
-
-
Solid Biosciences receives European orphan drug designation for SGT-003
-
-
-
-
-
-
-
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
-
-
-
-
-
-
-
Solid Biosciences receives FDA orphan drug status for gene therapy SGT-212
-
-
-
-
-
-
-
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
-
-
-
-
-
-
-
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Solid Biosciences (SLDB)
-
-
-
-
-
-
-
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
-
329,915 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

